Literature DB >> 35243594

Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?

Daniel M Kerekes1, Sajid A Khan2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35243594     DOI： 10.1245/s10434-022-11383-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  13 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Understanding the Intersections between Metabolism and Cancer Biology.

Authors:  Matthew G Vander Heiden; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Authors:  Shuhua Yue; Junjie Li; Seung-Young Lee; Hyeon Jeong Lee; Tian Shao; Bing Song; Liang Cheng; Timothy A Masterson; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 5.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.

Authors:  Michael N Mavros; Konstantinos P Economopoulos; Vangelis G Alexiou; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

6.  Actual long-term outcome of extrahepatic bile duct cancer after surgical resection.

Authors:  Jin-Young Jang; Sun-Whe Kim; Do Joong Park; Young Joon Ahn; Yoo-Seok Yoon; Min Gew Choi; Kyung-Suk Suh; Kuhn Uk Lee; Yong-Hyun Park
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

7.  ASO Visual Abstract: ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.

Authors:  Goro Ueno; Yoshifumi Iwagami; Shogo Kobayashi; Suguru Mitsufuji; Daisaku Yamada; Yoshito Tomimaru; Hirofumi Akita; Tadafumi Asaoka; Takehiro Noda; Kunihito Gotoh; Masaki Mori; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Ann Surg Oncol       Date:  2022-05       Impact factor: 5.344

Review 8.  Cholesterol metabolism and resistance to tamoxifen.

Authors:  Marc Poirot; Sandrine Silvente-Poirot; Ralph R Weichselbaum
Journal:  Curr Opin Pharmacol       Date:  2012-10-11       Impact factor: 5.547

9.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.

Authors:  Junjie Li; Xiaochao Qu; Jie Tian; Jian-Ting Zhang; Ji-Xin Cheng
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.